Dual inhibition of complement C5 and CD14 attenuates inflammation in a cord blood model.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
08
02
2022
accepted:
13
01
2023
revised:
20
12
2022
medline:
31
7
2023
pubmed:
2
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
Escherichia coli and Group B streptococci (GBS) are the main causes of neonatal early-onset sepsis (EOS). Despite antibiotic therapy, EOS is associated with high morbidity and mortality. Dual inhibition of complement C5 and the Toll-like receptor co-factor CD14 has in animal studies been a promising novel therapy for sepsis. Whole blood was collected from the umbilical cord after caesarean section (n = 30). Blood was anti-coagulated with lepirudin. C5 inhibitor (eculizumab) and anti-CD14 was added 8 min prior to, or 15 and 30 min after adding E. coli or GBS. Total bacterial incubation time was 120 min (n = 16) and 240 min (n = 14). Cytokines and the terminal complement complex (TCC) were measured using multiplex technology and ELISA. Dual inhibition significantly attenuated TCC formation by 25-79% when adding inhibitors with up to 30 min delay in both E. coli- and GBS-induced inflammation. TNF, IL-6 and IL-8 plasma concentration were significantly reduced by 28-87% in E. coli-induced inflammation when adding inhibitors with up to 30 min delay. The dual inhibition did not significantly reduce TNF, IL-6 and IL-8 plasma concentration in GBS-induced inflammation. Dual inhibition of C5 and CD14 holds promise as a potential future treatment for severe neonatal EOS. Neonatal sepsis can cause severe host inflammation with high morbidity and mortality, but there are still no effective adjunctive immunologic interventions available. Adding CD14 and complement C5 inhibitors up to 30 min after incubation of E. coli or Group B streptococci in a human umbilical cord blood model significantly reduced complement activation and cytokine release. Dual inhibition of C5 and CD14 is a potential future therapy to modulate systemic inflammation in severe cases of neonatal sepsis.
Sections du résumé
BACKGROUND
Escherichia coli and Group B streptococci (GBS) are the main causes of neonatal early-onset sepsis (EOS). Despite antibiotic therapy, EOS is associated with high morbidity and mortality. Dual inhibition of complement C5 and the Toll-like receptor co-factor CD14 has in animal studies been a promising novel therapy for sepsis.
METHODS
Whole blood was collected from the umbilical cord after caesarean section (n = 30). Blood was anti-coagulated with lepirudin. C5 inhibitor (eculizumab) and anti-CD14 was added 8 min prior to, or 15 and 30 min after adding E. coli or GBS. Total bacterial incubation time was 120 min (n = 16) and 240 min (n = 14). Cytokines and the terminal complement complex (TCC) were measured using multiplex technology and ELISA.
RESULTS
Dual inhibition significantly attenuated TCC formation by 25-79% when adding inhibitors with up to 30 min delay in both E. coli- and GBS-induced inflammation. TNF, IL-6 and IL-8 plasma concentration were significantly reduced by 28-87% in E. coli-induced inflammation when adding inhibitors with up to 30 min delay. The dual inhibition did not significantly reduce TNF, IL-6 and IL-8 plasma concentration in GBS-induced inflammation.
CONCLUSION
Dual inhibition of C5 and CD14 holds promise as a potential future treatment for severe neonatal EOS.
IMPACT
Neonatal sepsis can cause severe host inflammation with high morbidity and mortality, but there are still no effective adjunctive immunologic interventions available. Adding CD14 and complement C5 inhibitors up to 30 min after incubation of E. coli or Group B streptococci in a human umbilical cord blood model significantly reduced complement activation and cytokine release. Dual inhibition of C5 and CD14 is a potential future therapy to modulate systemic inflammation in severe cases of neonatal sepsis.
Identifiants
pubmed: 36725909
doi: 10.1038/s41390-023-02489-2
pii: 10.1038/s41390-023-02489-2
doi:
Substances chimiques
Complement C5
0
Interleukin-6
0
Interleukin-8
0
Cytokines
0
Lipopolysaccharide Receptors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
512-519Informations de copyright
© 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Vergnano, S., Sharland, M., Kazembe, P., Mwansambo, C. & Heath, P. Neonatal sepsis: an international perspective. Arch. Dis. Child. Fetal Neonatal Ed. 90, F220–F224 (2005).
pubmed: 15846011
pmcid: 1721871
Oza, S., Lawn, J. E., Hogan, D. R., Mathers, C. & Cousens, S. N. Neonatal Cause-of-death estimates for the early and late neonatal periods for 194 countries: 2000–2013. Bull. World Health Organ. 93, 19–28 (2014).
pubmed: 25558104
pmcid: 4271684
Stoll, B. J. et al. Early-onset neonatal sepsis 2015 to 2017, the rise of Escherichia coli, and the need for novel prevention strategies. JAMA Pediatr. 174, e200593 (2020).
pubmed: 32364598
pmcid: 7199167
Flannery, D. D., Edwards, E. M., Puopolo, K. M. & Horbar, J. D. Early-onset sepsis among very preterm infants. Pediatrics 148, e2021052456 (2021).
pubmed: 34493539
Wynn, J., Cornell, T. T., Wong, H. R., Shanley, T. P. & Wheeler, D. S. The host response to sepsis and developmental impact. Pediatrics 125, 1031–1041 (2010).
pubmed: 20421258
Hajishengallis, G., Reis, E. S., Mastellos, D. C., Ricklin, D. & Lambris, J. D. Novel mechanisms and functions of complement. Nat. Immunol. 18, 1288–1298 (2017).
pubmed: 29144501
pmcid: 5706779
Pietrocola, G. et al. The group B streptococcus–secreted protein Cip interacts with C4, preventing C3b deposition via the lectin and classical complement pathways. J. Immunol. 196, 385–394 (2016).
pubmed: 26608922
Ward, P. A. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4, 133–142 (2004).
pubmed: 15040586
De Jong, H. K., Van Der Poll, T. & Wiersinga, W. J. The systemic pro-inflammatory response in sepsis. J. Innate Immun. 2, 422–430 (2010).
pubmed: 20530955
Gabay, C. & Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340, 448–454 (1999).
pubmed: 9971870
Chauhan, N., Tiwari, S. & Jain, U. Potential biomarkers for effective screening of neonatal sepsis infections: an overview. Microb. Pathog. 107, 234–242 (2017).
pubmed: 28377234
Barratt‐Due, A., Pischke, S. E., Nilsson, P. H., Espevik, T. & Mollnes, T. E. Dual inhibition of complement and toll‐like receptors as a novel approach to treat inflammatory diseases—C3 or C5 emerge together with CD14 as promising targets. J. Leukoc. Biol. 101, 193–204 (2017).
pubmed: 27581539
Schüller, S. S. et al. Immunomodulation to prevent or treat neonatal sepsis: past, present, and future. Front. Pediatr. 6, 199 (2018).
pubmed: 30073156
pmcid: 6060673
Wynn, J. L. & Levy, O. Role of innate host defenses in susceptibility to early-onset neonatal sepsis. Clin. Perinatol. 37, 307–337 (2010).
pubmed: 20569810
pmcid: 2891962
Nilsen, N. J. et al. Cellular trafficking of lipoteichoic acid and toll‐like receptor 2 in relation to signaling; role of CD14 and CD36. J. Leukoc. Biol. 84, 280–291 (2008).
pubmed: 18458151
pmcid: 3178504
Lotz, S. et al. Highly purified lipoteichoic acid activates neutrophil granulocytes and delays their spontaneous apoptosis via CD14 and TLR2. J. Leukoc. Biol. 75, 467–477 (2004).
pubmed: 14673018
Skjeflo, E. W., Christiansen, D., Espevik, T., Nielsen, E. W. & Mollnes, T. E. Combined inhibition of complement and CD14 efficiently attenuated the inflammatory response induced by Staphylococcus aureus in a human whole blood model. J. Immunol. 192, 2857–2864 (2014).
pubmed: 24516199
Puopolo, K. M., Benitz, W. E., Zaoutis, T. E. & Diseases, C. O. I. Management of neonates born at ≥ 35 0/7 weeks’ gestation with suspected or proven early-onset bacterial sepsis. Pediatrics 142, e20182894 (2018).
pubmed: 30455342
Klingenberg, C., Kornelisse, R. F., Buonocore, G., Maier, R. F. & Stocker, M. Culture-negative early-onset neonatal sepsis—at the crossroad between efficient sepsis care and antimicrobial stewardship. Front. Pediatr. 6, 285 (2018).
pubmed: 30356671
pmcid: 6189301
Brekke, O.-L. et al. Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine-and growth factor-synthesis in human whole blood. Mol. Immunol. 45, 3804–3813 (2008).
pubmed: 18606453
Thorgersen, E. B. et al. Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood. Infect. Immun. 77, 725–732 (2009).
pubmed: 19047409
Egge, K. H. et al. Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood. Innate Immun. 20, 68–77 (2014).
pubmed: 23669326
Egge, K. H. et al. The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clin. Exp. Immunol. 181, 457–467 (2015).
pubmed: 25907631
pmcid: 4557382
Lau, C. et al. Chimeric anti-CD14 IgG/4 hybrid antibodies for therapeutic intervention in pig and human models of inflammation. J. Immunol. 191, 4769–4777 (2013).
pubmed: 24062486
pmcid: 3804170
Mollnes, T. E. et al. Essential role of the C5a receptor in E. coli–induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100, 1869–1877 (2002).
pubmed: 12176911
Bergseth, G. et al. An international serum standard for application in assays to detect human complement activation products. Mol. Immunol. 56, 232–239 (2013).
pubmed: 23787367
Schlapbach, L. J. et al. Differential role of the lectin pathway of complement activation in susceptibility to neonatal sepsis. Clin. Infect. Dis. 51, 153–162 (2010).
pubmed: 20528471
Eisen, D. P. & Minchinton, R. M. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin. Infect. Dis. 37, 1496–1505 (2003).
pubmed: 14614673
Harboe, M., Thorgersen, E. B. & Mollnes, T. E. Advances in assay of complement function and activation. Adv. Drug Deliv. Rev. 63, 976–987 (2011).
pubmed: 21664392
Zhao, X., Chen, Y.-X. & Li, C.-S. Predictive value of the complement system for sepsis-induced disseminated intravascular coagulation in septic patients in emergency department. J. Crit. Care 30, 290–295 (2015).
pubmed: 25547047
Raymond, S. L. et al. Immunological defects in neonatal sepsis and potential therapeutic approaches. Front. Pediatr. 5, 14 (2017).
pubmed: 28224121
pmcid: 5293815
Mohamed, M. A., Cunningham-Rundles, S., Dean, C. R., Hammad, T. A. & Nesin, M. Levels of pro-inflammatory cytokines produced from cord blood in-vitro are pathogen dependent and increased in comparison to adult controls. Cytokine 39, 171–177 (2007).
pubmed: 17884557
Østerholt, H. C., Lundeland, B., Sonerud, T., Saugstad, O. D. & Nakstad, B. The impact of hyaluronan on monocyte toll‐like receptor expression in term infant cord blood. Acta Paediatr. 101, 706–713 (2012).
pubmed: 22372604
Tatad, A. F. et al. Cytokine expression in response to bacterial antigens in preterm and term infant cord blood monocytes. Neonatology 94, 8–15 (2008).
pubmed: 18097152
Krueger, M. et al. Cord blood levels of interleukin-6 and interleukin-8 for the immediate diagnosis of early-onset infection in premature infants. Neonatology 80, 118–123 (2001).
Büscher, U. et al. IL-1β, IL-6, IL-8 and G-CSF in the diagnosis of early-onset neonatal infections. J. Perinat. Med. 28, 383–388 (2000).
Berner, R., Welter, P. & Brandis, M. Cytokine expression of cord and adult blood mononuclear cells in response to Streptococcus agalactiae. Pediatr. Res. 51, 304–309 (2002).
pubmed: 11861934
Kashlan, F. et al. Umbilical vein interleukin 6 and tumor necrosis factor alpha plasma concentrations in the very preterm infant. Pediatr. Infect. Dis. J. 19, 238–243 (2000).
pubmed: 10749467
Garred, P., Tenner, A. J. & Mollnes, T. E. Therapeutic targeting of the complement system: from rare diseases to pandemics. Pharmacol. Rev. 73, 792–827 (2021).
pubmed: 33687995
pmcid: 7956994
Keshari, R. S. et al. Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis. Proc. Natl Acad. Sci. USA 114, E6390–E6399 (2017).
pubmed: 28720697
pmcid: 5547645
Reiss, U. M. et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr. Blood Cancer 61, 1544–1550 (2014).
pubmed: 24777716
Greenbaum, L. A. et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 89, 701–711 (2016).
pubmed: 26880462
Olszyna, D. P. et al. Effect of IC14, an anti‐CD14 antibody, on plasma and cell‐associated chemokines during human endotoxemia. Eur. Cytokine Netw. 14, 158–162 (2003).
pubmed: 14656690
Huber-Lang, M. et al. Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice. J. Immunol. 192, 5324–5331 (2014).
pubmed: 24790148
pmcid: 4025614
Skjeflo, E. W. et al. Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis. Crit. Care 19, 1–8 (2015).
Nakstad, B., Sonerud, T. & Solevåg, A. L. Early detection of neonatal group B Streptococcus sepsis and the possible diagnostic utility of IL-6, IL-8, and CD11b in a human umbilical cord blood in vitro model. Infect. Drug Resist. 9, 171 (2016).
pubmed: 27468243
pmcid: 4944914
Eichberger, J., Resch, E. & Resch, B. Diagnosis of neonatal sepsis: the role of inflammatory markers. Front. Pediatr. 10, 840288 (2022).
pubmed: 35345614
pmcid: 8957220
Mathews, J. H., Klesius, P. H. & Zimmerman, R. A. Opsonin system of the group B Streptococcus. Infect. Immun. 10, 1315–1320 (1974).
pubmed: 4215762
pmcid: 423105
Draper, D. W., Bethea, H. N. & He, Y.-W. Toll-like receptor 2-dependent and-independent activation of macrophages by Group B Streptococci. Immunol. Lett. 102, 202–214 (2006).
pubmed: 16242782